Leonteq Securities AG Makes New $2.12 Million Investment in DexCom, Inc. $DXCM

Leonteq Securities AG acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 31,965 shares of the medical device company’s stock, valued at approximately $2,122,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CVA Family Office LLC grew its position in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares in the last quarter. ORG Partners LLC grew its position in DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares in the last quarter. Spire Wealth Management grew its position in DexCom by 113.8% during the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after purchasing an additional 305 shares in the last quarter. Aventura Private Wealth LLC purchased a new position in DexCom during the 4th quarter worth approximately $43,000. Finally, Rothschild Investment LLC grew its holdings in shares of DexCom by 59.9% during the 3rd quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 245 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Trading Up 6.7%

DexCom stock opened at $71.44 on Thursday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The company’s fifty day simple moving average is $63.38 and its 200-day simple moving average is $65.84. The stock has a market cap of $27.57 billion, a P/E ratio of 30.53, a P/E/G ratio of 1.11 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the business earned $0.32 EPS. DexCom’s quarterly revenue was up 15.0% compared to the same quarter last year. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the sale, the director owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Friday, May 15th. The shares were sold at an average price of $59.91, for a total transaction of $101,847.00. Following the completion of the sale, the executive vice president directly owned 109,504 shares of the company’s stock, valued at approximately $6,560,384.64. The trade was a 1.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 6,112 shares of company stock valued at $379,990. 0.28% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. TD Cowen lowered their price target on shares of DexCom from $84.00 to $75.00 and set a “buy” rating on the stock in a report on Friday, May 1st. BTIG Research restated a “buy” rating and set a $85.00 price target on shares of DexCom in a report on Monday, March 9th. William Blair upgraded shares of DexCom to a “strong-buy” rating in a report on Friday, May 15th. Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Monday. Finally, Weiss Ratings upgraded shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $82.21.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.